|Bid||1.8100 x 4000|
|Ask||1.8400 x 800|
|Day's Range||1.8000 - 1.8900|
|52 Week Range||0.8800 - 4.3400|
|Beta (5Y Monthly)||0.40|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 28, 2022 - Apr 01, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.33|
Aridis Pharmaceuticals (ARDS) delivered earnings and revenue surprises of -650% and 97.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its second quarter ended June 30, 2022.
Aridis Pharmaceuticals Inc's (NASDAQ: ARDS) inhaled treatment of its fully human monoclonal antibody cocktail AR-701 resulted in no detectable SARS-CoV-2 virus in the lungs of infected non-human primates. The candidate also protected their lungs from disease. AR-701 was effective in non-human primates when used either as a prophylactic or therapeutic treatment regimen. Inhaled AR-701 substantially reduced and continued to suppress the viral load in the nasal sinus and oropharynx (upper respirato